Neve Yarak, Israel — February 2, 2026 — Leads & Copy — N2OFF, Inc. (NASDAQ: NITO) has highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd., its wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.
The study, titled “SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier (AAC3) as a structural case study,” was published online on December 30, 2025. The work integrates transcriptomic data from NASA’s Open Science Data Repository (OSDR), examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells (hBMSCs), and mouse brain tissue exposed to microgravity and spaceflight-related stressors.
The analysis identified differential regulation of multiple SLC25A carriers under spaceflight conditions, supporting their potential utility as biomarkers of mitochondrial and metabolic dysfunction. The ADP/ATP carrier AAC3 was further examined as a structural case study, based on comparative modeling and structure–function analyses to illustrate how carrier conformational features may be targeted to rescue mitochondrial bioenergetics under stress.
While this independent academic research, conducted in collaboration with the University of Bari “Aldo Moro” and the University of Pittsburgh, was not performed under MitoCareX Bio’s auspices, it directly aligns with the Company’s core scientific area of focus on mitochondrial carrier biology. MitoCareX Bio applies proprietary approaches, including the MITOLINE™ algorithm to virtually model, screen and validate small-molecule modulators targeting the SLC25A family of mitochondrial carriers. These proteins, central to cellular energy metabolism, play central roles in hard-to-treat indications including in several types of cancer, metabolic diseases related to the metabolic syndrome, and are also implicated in rare inherited disorders associated with neuromuscular degeneration, which share mechanistic similarities with physiologicl alterations observed in astronauts.
Prof. Ciro Leonardo Pierri’s expertise in structural biology, mitochondrial carriers and drug targeting, demonstrated through his contributions to this and other related publications, underpins the foundational science driving MitoCareX Bio’s precision pipeline.
The full article is available open access at: https://doi.org/10.1186/s12967-025-07505-z.
N2OFF owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer and inflammatory metabolic diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build ) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd
N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.
Source: N2OFF Inc
